M&A Deal Summary

New Day Diagnostics Acquires Epigenomics

On July 24, 2023, New Day Diagnostics acquired medical products company Epigenomics for 12M USD

Acquisition Highlights
  • This is New Day Diagnostics’ 1st transaction in the Medical Products sector.
  • This is New Day Diagnostics’ largest (disclosed) transaction.
  • This is New Day Diagnostics’ 1st transaction in Germany.

M&A Deal Summary
Date 2023-07-24
Target Epigenomics
Sector Medical Products
Buyer(s) New Day Diagnostics
Deal Type Add-on Acquisition
Deal Value 12M USD

Target

Epigenomics

Berlin, Germany
Epigenomics is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics developed blood tests for various cancer indications with high unmet medical need. Epigenomics is based in Berlin, Germany.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

New Day Diagnostics

Knoxville, Tennessee, United States
Category Company
Sector Medical Products
DESCRIPTION

New Day Diagnostics is a full-service diagnostics and CRO services company specializes in designing, developing, and bring to market diagnostic tests. New Day Diagnostics is based in Knoxville, Tennessee.

DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Germany) 1 of 1
Year (2023) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal